Marshall Wace Books $700 Million Gain on Circle's Hot IPO
Marshall Wace's XO Digital Finance Fund, in which its flagship Eureka hedge fund is the principal investor, recorded an estimated 47% internal rate of return on its investment, according to a person familiar with the deal. A spokesperson for Marshall Wace declined to comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
BellRing Brands (BRBR) To Report Earnings Tomorrow: Here Is What To Expect
Nutrition products company Bellring Brands (NYSE:BRBR) will be reporting earnings this Monday after market hours. Here's what you need to know. BellRing Brands beat analysts' revenue expectations by 1.6% last quarter, reporting revenues of $588 million, up 18.9% year on year. It was a mixed quarter for the company, with a solid beat of analysts' organic revenue estimates but a significant miss of analysts' gross margin estimates. Is BellRing Brands a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting BellRing Brands's revenue to grow 3.2% year on year to $531.8 million, slowing from the 15.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.50 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BellRing Brands has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 2.6% on average. Looking at BellRing Brands's peers in the shelf-stable food segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Hershey delivered year-on-year revenue growth of 26%, beating analysts' expectations by 3.1%, and Lamb Weston reported revenues up 4%, topping estimates by 5.7%. Hershey's stock price was unchanged after the resultswhile Lamb Weston was up 19.3%. Read our full analysis of Hershey's results here and Lamb Weston's results here. The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the shelf-stable food stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 2.4% on average over the last month. BellRing Brands is down 5.5% during the same time and is heading into earnings with an average analyst price target of $78.33 (compared to the current share price of $54.11). Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a few seconds ago
- Yahoo
MSA Safety (MSA) Reports Q2: Everything You Need To Know Ahead Of Earnings
Safety equipment manufacturer MSA Safety (NYSE:MSA) will be reporting results this Monday afternoon. Here's what to look for. MSA Safety beat analysts' revenue expectations by 5% last quarter, reporting revenues of $421.3 million, up 1.9% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts' EPS estimates. Is MSA Safety a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting MSA Safety's revenue to decline 3.2% year on year to $447.8 million, a reversal from the 3.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.76 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. MSA Safety has missed Wall Street's revenue estimates three times over the last two years. Looking at MSA Safety's peers in the business services & supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. HNI delivered year-on-year revenue growth of 7%, beating analysts' expectations by 3.2%, and MillerKnoll reported revenues up 8.2%, topping estimates by 5.3%. HNI's stock price was unchanged after the resultswhile MillerKnoll was up 12.2%. Read our full analysis of HNI's results here and MillerKnoll's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the business services & supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.4% on average over the last month. MSA Safety is up 2.2% during the same time and is heading into earnings with an average analyst price target of $182.20 (compared to the current share price of $175.23). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
a few seconds ago
- Yahoo
What To Expect From Vertex Pharmaceuticals's (VRTX) Q2 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting earnings this Monday after the bell. Here's what to look for. Vertex Pharmaceuticals missed analysts' revenue expectations by 2.3% last quarter, reporting revenues of $2.77 billion, up 3% year on year. It was a disappointing quarter for the company, with a significant miss of analysts' EPS estimates and full-year revenue guidance slightly missing analysts' expectations. Is Vertex Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Vertex Pharmaceuticals's revenue to grow 9.8% year on year to $2.90 billion, improving from the 6.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.25 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Vertex Pharmaceuticals has missed Wall Street's revenue estimates three times over the last two years. Looking at Vertex Pharmaceuticals's peers in the therapeutics segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 7.3%, beating analysts' expectations by 13.7%, and Moderna reported a revenue decline of 41.1%, topping estimates by 10.7%. Biogen traded up 3.9% following the results. Read our full analysis of Biogen's results here and Moderna's results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Vertex Pharmaceuticals's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $505.19 (compared to the current share price of $464). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
